• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by RenovoRx Inc.

    5/7/25 4:34:20 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RNXT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    RenovoRx, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    75989R107

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    75989R107


    1Names of Reporting Persons

    AWM Investment Company, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,285,000.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,285,000.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,285,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.3 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:  AWM Investment Company, Inc., a Delaware Corporation (AWM), is the investment adviser to Special Situations Cayman Fund, L.P. (CAYMAN), Special Situations Fund III QP, L.P. (SSFQP) and Special Situations Life Sciences Fund, L.P. (SSLS). (CAYMAN, SSFQP, and SSLS will hereafter be referred to as the Funds). As the investment adviser to the Funds, AWM holds sole voting and investment power over 1,300,500 shares of Common Stock of the Issuer (the Shares) held by SSFQP, 362,500 shares of Common Stock held by CAYMAN and 622,000 shares of Common Stock held by SSLS


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    RenovoRx, Inc.
    (b)Address of issuer's principal executive offices:

    2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW, CALIFORNIA, 94040
    Item 2. 
    (a)Name of person filing:

    The person filing this report is AWM Investment Company, Inc., a Delaware corporation (AWM), which is the investment adviser to Special Situations Cayman Fund, L.P., a Cayman Islands Limited Partnership, Special Situations Fund III QP, L.P., a Delaware limited partnership and Special Situations Life Sciences Fund, L.P., a Delaware limited partnership, The principal business of each Fund is to invest in equity and equity-related securities and other securities of any kind or nature. David M. Greenhouse (Greenhouse) and Adam C. Stettner (Stettner) are members of: SSCayman, L.L.C., a Delaware limited liability company (SSCAY), the general partner of CAYMAN; MGP Advisers Limited Partnership, a Delaware limited partnership (MGP), the general partner of SSFQP and LS Advisers, L.L.C., a New York limited liability company (LS). Greenhouse and Stettner are also controlling principals of AWM.
    (b)Address or principal business office or, if none, residence:

    527 Madison Avenue, Suite 2600 New York, NY 10022
    (c)Citizenship:

    AWM is a Delaware Corporation
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    75989R107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    2,285,000
    (b)Percent of class:

    6.3  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    AWM is the investment adviser to each of the Funds. As the investment adviser to the Funds, AWM holds sole voting power over 1,300,500 shares of Common Stock of the Issuer (the Shares) held by SSFQP, 362,500 shares of Common Stock held by CAYMAN and 622,000 shares of Common Stock held by SSLS. Greenhouse and Stettner are members of: SSCAY, the general partner of CAYMAN; MGP, the general partner of SSFQP; MG, the general partner of SSPE; and LS, the general partner of SSLS. Greenhouse and Stettner are also controlling principals of AWM.

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    AWM is the investment adviser to each of the Funds. As the investment adviser to the Funds, AWM holds sole investment power over 1,300,500 shares of Common Stock of the Issuer (the Shares) held by SSFQP, 362,500 shares of Common Stock held by CAYMAN and 622,000 shares of Common Stock held by SSLS. Greenhouse and Stettner are members of: SSCAY, the general partner of CAYMAN; MGP, the general partner of SSFQP; MG, the general partner of SSPE; and LS, the general partner of SSLS. Greenhouse and Stettner are also controlling principals of AWM.

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    AWM Investment Company, Inc.
     
    Signature:Adam Stettner
    Name/Title:Executive Vice President
    Date:05/07/2025
    Get the next $RNXT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RNXT

    DatePrice TargetRatingAnalyst
    11/1/2021$16.00Buy
    Roth Capital
    10/6/2021$15.00Buy
    Maxim Group
    More analyst ratings

    $RNXT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Agah Ramtin bought $13,500 worth of shares (15,000 units at $0.90), increasing direct ownership by 1% to 1,113,460 units (SEC Form 4)

      4 - RenovoRx, Inc. (0001574094) (Issuer)

      4/17/25 6:10:32 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Bagai Shaun bought $6,821 worth of shares (7,500 units at $0.91), increasing direct ownership by 2% to 320,040 units (SEC Form 4)

      4 - RenovoRx, Inc. (0001574094) (Issuer)

      4/16/25 6:08:22 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Agah Ramtin bought $16,000 worth of shares (20,000 units at $0.80), increasing direct ownership by 2% to 1,098,460 units (SEC Form 4)

      4 - RenovoRx, Inc. (0001574094) (Issuer)

      4/14/25 6:30:30 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

      Patent Expands Protection of TAMP therapy platform, Including Methods to Deliver an Agent, such as a Chemotherapeutic Drug, Near a Tumor RenovoRx Currently Holds a Strong and Growing IP Portfolio with 19 Issued Patents and 12 Pending Patents Supporting the Commercialization of RenovoCath Device RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that it has received an Issue Notification from the U.S. Patent and Trademark Office (USPTO) indicating that U.S. patent NO. 12,290,564, becomes effective today, May 6, 2025.

      5/6/25 8:30:00 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET

      RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced it will host its first quarter 2025 financial results conference call on May 15th, 2025, at 4:30 p.m. ET. Additional details will be available in the Investor Relations section of the Company's website at https://ir.renovorx.com/. Event: RenovoRx First Quarter 2025 Financial Results Conference Call Date: Thursday, May 15, 2025 Time: 4:30 p.m. ET Live Call: 1-877-407-4018 (U.S. Toll Free) or 1-201-689-8471 (International) Webcast:

      5/1/25 8:30:00 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial

      Johns Hopkins Medicine's Valerie Lee, MD joins Michael J. Pishvaian, MD in an Appointed Key Role for TIGeR-PaC Trial By becoming an additional clinical site for TIGeR-PaC, Johns Hopkins Medicine joins several esteemed cancer centers to support RenovoRx's initiative to complete patient enrollment for the trial during 2025 RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that Johns Hopkins Medicine is now initiated to enroll patients with locally advanced pancreatic cancer (LAPC) in RenovoRx's ongoing Phase III TIGeR

      4/29/25 8:30:00 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by RenovoRx Inc. (Amendment)

      SC 13G/A - RenovoRx, Inc. (0001574094) (Subject)

      2/14/23 4:51:34 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by RenovoRx Inc.

      SC 13G - RenovoRx, Inc. (0001574094) (Subject)

      4/14/22 2:24:24 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by RenovoRx Inc.

      SC 13G - RenovoRx, Inc. (0001574094) (Subject)

      2/14/22 6:33:04 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Marton Laurence exercised 20,480 shares at a strike of $0.15, increasing direct ownership by 45% to 66,164 units (SEC Form 4)

      4 - RenovoRx, Inc. (0001574094) (Issuer)

      5/6/25 4:10:20 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Agah Ramtin bought $13,500 worth of shares (15,000 units at $0.90), increasing direct ownership by 1% to 1,113,460 units (SEC Form 4)

      4 - RenovoRx, Inc. (0001574094) (Issuer)

      4/17/25 6:10:32 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Bagai Shaun

      4 - RenovoRx, Inc. (0001574094) (Issuer)

      4/16/25 5:18:21 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    Leadership Updates

    Live Leadership Updates

    See more
    • RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

      LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships. Mr. Witt's appointment highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities not only for its RenovoGem™ investigational combination product (currently in Phase III clinical development), but also opportunities with the Company's foundational FDA

      6/10/24 8:30:00 AM ET
      $IMMX
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RenovoRx Closes $6.1 Million Private Placement

      With Material Participation From Insiders, Offering Proceeds to Help Drive Company Towards Second Interim Analysis of the Pivotal TIGeR-PaC Phase III Clinical Trial by Late 2024 RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that it has closed a private placement (the "private placement" or the "financing") resulting in gross proceeds of approximately $6.1 million, before deducting offering expenses. The closing of this private placement extends RenovoRx's cash runway as RenovoRx continues its ongoing pivotal TIGeR-PaC Phase III c

      1/29/24 8:30:00 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.

      RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Michel Ducreux, M.D., Ph.D. to the Company's Scientific Advisory Board (SAB). Dr. Ducreux is the Head of the Gastrointestinal Oncology Unit and Gastrointestinal Oncology Tumor Board at Gustave Roussy, Professor of Oncology at Paris-Saclay University in France, and Vice-Chair of ESMO GI. Dr. Ducreux was trained in medicine, gastroenterology, and gastrointestinal tract oncology at the University of Paris Sud. Dr. Ducreux earned his master's degree in biological sciences and PhD in health sciences. He has held pre

      11/16/23 8:35:00 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital initiated coverage on RenovoRx with a new price target

      Roth Capital initiated coverage of RenovoRx with a rating of Buy and set a new price target of $16.00

      11/1/21 11:49:10 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on RenovoRx with a new price target

      Maxim Group initiated coverage of RenovoRx with a rating of Buy and set a new price target of $15.00

      10/6/21 8:24:28 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    Financials

    Live finance-specific insights

    See more
    • RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET

      RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced it will host its first quarter 2025 financial results conference call on May 15th, 2025, at 4:30 p.m. ET. Additional details will be available in the Investor Relations section of the Company's website at https://ir.renovorx.com/. Event: RenovoRx First Quarter 2025 Financial Results Conference Call Date: Thursday, May 15, 2025 Time: 4:30 p.m. ET Live Call: 1-877-407-4018 (U.S. Toll Free) or 1-201-689-8471 (International) Webcast:

      5/1/25 8:30:00 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by RenovoRx Inc.

      SCHEDULE 13G - RenovoRx, Inc. (0001574094) (Subject)

      5/8/25 7:44:41 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by RenovoRx Inc.

      SCHEDULE 13G - RenovoRx, Inc. (0001574094) (Subject)

      5/7/25 4:34:20 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by RenovoRx Inc.

      DEF 14A - RenovoRx, Inc. (0001574094) (Filer)

      4/30/25 5:13:07 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care